Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Systemic Lupus Erythematosus
jRCT2080223916Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Ustekinumab with Placebo / Ustekinumab crossover (2 arms). Started May 2018; status: completed.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080223916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223916.